Ophthalmoplegia in Mitochondrial Disease by 나지훈 et al.
1190 www.eymj.org
INTRODUCTION
Mitochondrial disease is a complex and heterogeneous multi-
system disorder that is caused by mitochondrial dysfunction, 
particularly defects in the mitochondrial respiratory chain 
(MRC) complex and related aberrant oxidative phosphoryla-
tion.1 Mitochondrial disease has dual origins: it may develop 
because of deformities in mitochondrial DNA (mtDNA) or 
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Purpose: To evaluate the classification, diagnosis, and natural course of ophthalmoplegia associated with mitochondrial disease. 
Materials and Methods: Among 372 patients with mitochondrial disease who visited our hospital between January 2006 and Janu-
ary 2016, 21 patients with ophthalmoplegia were retrospectively identified. Inclusion criteria included onset before 20 years of age, 
pigmentary retinopathy, and cardiac involvement. The 16 patients who were finally included in the study were divided into three 
groups according to disease type: Kearns-Sayre syndrome (KSS), KSS-like, and chronic progressive external ophthalmoplegia (CPEO). 
Results: The prevalences of clinical findings were as follows: ptosis and retinopathy, both over 80%; myopathy, including extraoc-
ular muscles, 75%; lactic acidosis, 71%; and elevated levels of serum creatine kinase, 47%. Half of the patients had normal mag-
netic resonance imaging findings. A biochemical enzyme assay revealed mitochondrial respiratory chain complex I defect as the 
most common (50%). The prevalence of abnormal muscle findings in light or electron microscopic examinations was 50% each, 
while that of large-scale mitochondrial DNA (mtDNA) deletions in a gene study was 25%. We compared the KSS and KSS-like 
groups with the CPEO patient group, which showed pigmentary retinopathy (p<0.001), cardiac conduction disease (p=0.013), 
and large-scale mtDNA deletions (p=0.038). KSS and KSS-like groups also had gastrointestinal tract disorders such as abnormal 
gastrointestinal motility (p=0.013) unlike the CPEO group.
Conclusion: Patients with KSS had gastrointestinal symptoms, which may indicate another aspect of systemic involvement. The 
presence of large-scale mtDNA deletions was an objective diagnostic factor for KSS and a gene study may be helpful for evaluat-
ing patients with KSS.
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nuclear DNA at the genetic level.2 These conditions can cause 
numerous phenotypes and genotypes of mitochondrial dis-
eases, leading to the involvement of multiple organs, with 
variations in the extent and severity of the manifestations, as 
well as different clinical outcomes.3 Because of this complexi-
ty, mitochondrial disease may present with any symptom in 
any organ at any age.4
Mitochondrial diseases that involve ocular symptoms as a 
major manifestation include chronic progressive external 
ophthalmoplegia (CPEO) and Kearns-Sayre syndrome (KSS), 
among others.5 CPEO, a comparably mild mitochondrial dis-
ease, is characterized by weakness in the extraocular muscles 
and ptosis, and it is often accompanied by limb weakness.6 
Ptosis typically progresses to ophthalmoparesis over months 
or years.7 KSS is defined as CPEO that begins before 20 years 
of age, is accompanied by pigmentary retinopathy, and is as-
sociated with at least one of the following: cardiac conduction 
deficits, cerebellar ataxia, or an elevated cerebrospinal fluid 
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protein concentration.6
Mitochondrial diseases with ophthalmoplegia, such as KSS, 
are very rare, and the natural courses of these types of diseas-
es are not well known. Therefore, in this study, we systemati-
cally reviewed the clinical characteristics, diagnosis, and natu-
ral courses of mitochondrial diseases with ophthalmoplegia.6
MATERIALS AND METHODS
 
Patients and study design 
We retrospectively reviewed the medical records of 372 pa-
tients with mitochondrial disease who were followed up regu-
larly at our hospital between January 2006 and January 2016 
(Fig. 1). We identified 21 patients with ophthalmoplegia 
symptoms out of the 372 patients with mitochondrial disease, 
although five patients who were lost to follow-up were ex-
cluded. The final study population included 16 patients with 
mitochondrial disease and symptoms of ophthalmoplegia. All 
patients satisfied the modified criteria for mitochondrial dis-
ease proposed by Bernier, et al.,8 which include clinical, histo-
pathological, enzymatic, and metabolic parameters. The pa-
tients were classified into three groups: KSS, KSS-like, and 
CPEO. KSS is defined as CPEO that begins before 20 years of 
age and is accompanied by pigmentary retinopathy and car-
diac conduction disease. Patients were placed in the KSS-like 
group if they had KSS without cardiac conduction disease. 
The other patients were placed in the CPEO group, regardless 
of age. Clinical severity was defined as follows: mild, ambula-
tory and/or independent for daily activities; moderate, wheel-
chair-bound and/or partially dependent for daily activities; 
severe, bedridden and totally dependent for daily activities; 
and deceased. The study was approved by the Institutional 
Review Board of the Yonsei University Gangnam Severance 
Hospital (3-2017-0168). Informed consent was obtained from 
parents or legal guardians for all diagnostic procedures and 
molecular studies.
Collection of data regarding clinical characteristics 
and diagnostic evaluation
Disease-related clinical variables were collected, including the 
type of the first symptom, family history, age of onset of ocular 
myopathy, age of onset of the first symptom, duration from the 
first symptom to the last outpatient visit, and clinical severity at 
the last outpatient visit. Muscle biopsy was performed, and the 
samples were assessed via routine histology, immunohisto-
chemistry, and electron microscopy examinations.9
We analyzed diagnostic data obtained from histopathologi-
cal examinations, enzymatic assays for MRC, laboratory tests, 
neuroimaging studies, and a gene study. We used a strategy 
based on long PCR for analysis of mtDNA from the patients. 
PCR primer sets were designed to cover the KSS common de-
letion mtDNA 5-kb and 7.4-kb deletion breakpoint. All PCR 
products were directly sequenced in both directions.
Syndromic diagnosis was performed. If a patient’s serum 
lactate level was at least two times the normal value, the level 
was considered as severely increased; serum lactate levels 
above normal (0.5–2.2 mmol/L), but less than two times the 
normal value, were considered as mildly increased. Serum 
creatine kinase levels were classified in a similar manner.
Statistical analysis
All statistical analyses were conducted using Statistical Pack-
age for the Social Sciences (SPSS), version 20.0 (IBM Corp., 
Armonk, NY, USA). The data are expressed as medians and 
interquartile ranges. Because our study population was small, 
the KSS and KSS-like groups were combined and compared 
with the CPEO group. Fischer’s exact tests and chi-square 
tests were used to evaluate differences between the groups. 
Mann-Whitney U tests were used to analyze the duration-re-




Among the 16 included patients, nine (56.3%) were male (Ta-
ble 1). The nature of the initial symptoms varied, with oph-
thalmoplegia (six patients, 38%) and ptosis (six patients, 38%) 
being the most prevalent, followed by exercise intolerance 
(two patients, 13%), afebrile seizure (one patient, 6%), and vi-
sual disturbance (one patient, 6%). Most patients (12 patients, 
75%) had no family history of the disease. The age at onset of 
the first symptom was 11.9 (6.0–16.4) years. The duration from 
The patients with mitochondrial disease in Gangnam Serverance Hospital (n=372)
Mitochondrial disease patients with ophthalmoplegia (n=21, 6%)
Mitochondrial disease patients with ophthalmoplegia (n=16, 4.3%)
KSS (n=5) KSS-like (n=3) CPEO (n=8)
Lost to follow up (n=5)
Fig. 1. Flowchart showing the recruitment of patients with mitochondrial 
disease and ophthalmoplegia. KSS, Kearns-Sayre syndrome; CPEO, 
chronic progressive external ophthalmoplegia.
1192
Ophthalmoplegia and Mitochondrial Disease
https://doi.org/10.3349/ymj.2018.59.10.1190
the first symptom to the last outpatient clinic visit was 11.8 
(6.3–17.9) years. Most patients showed ocular myopathy be-
fore the age of 20 years (13 patients, 81%). At the last outpa-
tient clinic visit, one patient was deceased, one patient 
showed moderate clinical severity (wheelchair-bound and/or 
partially dependent for daily activities), and the other patients 
showed mild clinical severity (14 patients, 88%).
Clinical features 
All patients had ophthalmoplegia. Other notable dysfunctions 
included pigmentary retinopathy or ptosis (14 and 13 patients, 
respectively), gastrointestinal tract disorders (five patients, 
31%), cardiac involvement [five patients (31%) had a cardiac 
conduction system defect, and three of them had received a 
pacemaker (19%)], auditory issues (three patients, 19%), and 
respiratory issues (three patients, 19%) (Table 2). Three quar-
ters of the patients had extraocular myopathy. Endocrine dys-
function was found in four patients (25%) (Table 2).
 
Diagnostic evaluations 
Of the 16 patients with mitochondrial disease and ophthal-
moplegia, five (31%) were diagnosed with KSS, three (19%) 
with KSS-like, and eight (50%) with CPEO (Table 3).
Mild or severe elevations in serum lactate levels were found in 
10 patients (71%), while mild or severe elevations in serum cre-
atine kinase levels were observed in seven patients (47%). Brain 
magnetic resonance imaging (MRI) showed abnormal findings 
in seven of 14 patients (two did not have MRI results), revealing 
atrophy or abnormal signals in various areas of the brain. 
Muscle biopsy, performed for 10 of the 16 patients, showed 
abnormal changes under a light microscope in five patients 
(50%), including findings for nonspecific diseases (one pa-
tient) and specific mitochondrial diseases (four patients), 
such as ragged red fibers and abnormal staining. Abnormal 
findings under an electron microscope were observed in five 
patients (50%): these included pleoconia (two patients), 
megaconia (one patient), and both (two patients). Biochemi-
cal evaluation of MRC enzymatic function in the muscle tis-
sue of 10 patients (no results were available for six patients) 
showed defects in MRC complex I and MRC complex IV in 
five (50%) and one patient (10%), respectively. Genetic analy-
sis was performed for all patients and revealed large-scale 
mtDNA deletions in four patients (25%). All four patients car-
ried mtDNA 4977 bp common deletions (nt8482–nt13460).
Comparisons of clinical variables among the three 
groups 
Our study population was divided into three groups (KSS, KSS-
like, and CPEO); however, because the group sizes were small, 
the KSS and KSS-like groups were combined for comparison 
with the CPEO group (Table 4). There were no significant dif-
ferences between the KSS/KSS-like group and the CPEO group 
in terms of sex, type of initial symptoms, family history, and 
Table 1. Clinical Characteristics of 16 Patients with Mitochondrial Dis-








Exercise intolerance 2 (13)
Afebrile seizure 1 (6)
Visual disturbance 1 (6)
Family history
Mitochondrial disease 1 (6)
Nonspecific neurological disease 3 (19)
None 12 (75)
Age of onset of first symptom (yr) 11.9 (6.0–16.4)
Duration from first symptom to last outpatient visit (yr) 11.8 (6.3–17.9)
Age at muscle biopsy (n=12; yr) 17.5 (13.3–27.4)
Age at initiation of cocktail therapy (yr) 20.0 (13.3–27.4)
Age at last outpatient visit (yr) 22.5 (14.8–24.9)
Age of onset of ocular myopathy
Onset before 20 years of age 13 (81)
Onset after 20 years of age 3 (19)
Clinical severity at last outpatient visit
Mild (ambulatory and/or independent for daily activities) 14 (88)
Moderate (wheelchair-bound and/or partially dependent 
for daily activities)
1 (6)
Severe (bedridden, total dependent for daily activities) 0 (0)
Death 1 (6)
Data are presented as a median (Interquartile range) or number (percentages).




Progressive external ophthalmoplegia 16 (100)
Pigmentary retinopathy 14 (88)
Ptosis 13 (81)
Ear (sensorineural hearing loss) 3 (19)
Respiratory system 3 (19)
Gastrointestinal tract 5 (31)
Heart
Abnormal conduction 5 (31)
Pacemaker treatment 3 (19)
Neuromuscular system
Myopathy (extraocular) 12 (75)
Seizure 4 (25)
Ataxia 1 (6)
Peripheral neuropathy 1 (6)
Endocrine system 4 (25)
Data are presented as numbers (percentages).
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the age at onset of ocular myopathy. In addition, there were no 
significant differences in the duration from birth to the first 
symptom, duration from the first symptom to the last outpa-
tient clinic visit, and clinical severity at the last outpatient visit. 
As opposed to the CPEO group, the KSS/KSS-like group showed 
pigmentary retinopathy (p<0.001) and cardiac conduction dis-
ease (p=0.013). In addition, the KSS/KSS-like group also had 
gastrointestinal tract disorders, such as abnormal gastrointes-
tinal motility (p=0.013), unlike the CPEO group. 
There were no significant differences between the groups 
with regard to lactic acidosis, elevation of serum creatine ki-
nase levels, brain MRI findings, and results from biochemical 
enzyme and histopathological assays. The prevalence of large-
scale mtDNA deletions was significantly higher in the KSS/
KSS-like group than in the CPEO group (p=0.038).
DISCUSSION
The clinical features of mitochondrial diseases vary greatly, 
creating challenges to their diagnosis and management.10 Pe-
ripheral neuropathy, muscle weakness or atrophy, hypotonia 
or hypertonia, cerebellar ataxia, and leukodystrophy have fre-
quently been described as presenting symptoms.4,11,12 Predom-
inant neuromuscular and ophthalmological symptoms, such 
as strabismus, ptosis, ophthalmoplegia, optic atrophy with 
progressive loss of vision, nystagmus, and retinitis pigmentosa, 
are also observed.11 Mitochondrial diseases with ophthalmo-
plegia include KSS, CPEO, and Pearson syndrome (PS).13 Be-
cause the diagnosis of mitochondrial disease is difficult, there 
have been few studies about this condition. The most common 
initial symptom of mitochondrial disease involves the neuro-
muscular system.4,11 However, in our study population, the 
most common initial symptom was an ocular symptom.
In one of the few studies that have reported on this topic, 
Grönlund, et al.13 found that the prevalence of ophthalmople-
gia in patients with mitochondrial disease was 38.6% (22/57), 
and ophthalmoscopy, which is performed in patients with 
mitochondrial disease, revealed pigmentation in the macula 
and/or periphery in 29.6% (16/54) patients. Although a few 
previous studies have reported on the prevalence of ophthal-
moplegia, results vary depending on how the patient groups 
were formed. Consequently, ophthalmoplegia symptoms 
may be an important issue in patients with mitochondrial dis-
ease. Moreover, it is important to perform an ophthalmologi-
cal evaluation, including precise retinal examinations, such as 
ophthalmoscopy, in patients with mitochondrial disease who 
exhibit ocular symptoms, such as ophthalmoplegia. Six per-
cent of the patients with mitochondrial disease in our study 
had ophthalmoplegia. In addition, more than 80% patients 
had pigmentary retinopathy. 
The mean age at onset of the first symptom in our study was 
12.8 years, which is later than that for other mitochondrial 
diseases.11 In a study by Han, et al.,14 all patients with Leigh 
syndrome and esotropia reported disease onset at less than 1 
year of age. In another study, Munnich, et al.11 reported that 
neonatal (before 1 month, 36%) and infantile (1–24 months, 
44%) onset were frequently observed. However, most report-
ed cases of KSS have shown that symptoms develop after 10 
years of age.15-17 These findings indicate that the age of onset 
of symptoms is a variable clinical characteristic. In mitochon-
drial diseases, such as KSS and CPEO, where ophthalmople-
gia is a major finding, the onset of ocular and other symptoms 
might be delayed. We, therefore, assume that symptoms and 
the age of onset vary according to the type of mitochondrial 
disease and suggest that these factors should be noted and 
considered in clinical practice.
Table 3. Diagnostic Evaluation of 16 Patients with Mitochondrial Dis-















Basal ganglia signal abnormality 3 (21)
Thalamus signal abnormality 4 (29)




Cortex signal abnormality 1 (7)
White matter signal abnormality 5 (36)
Diffuse atrophy 1 (7)
Cerebellar atrophy 2 (14)
Biochemical enzyme assay 
(n=10)
MRC complex I defect 5 (50)
MRC complex IV defect 1 (10)
Normal 4 (40)
Histopathological analysis  
of muscle specimens under  
a light microscope (n=10)
Pathological findings in  
mitochondria
4 (40)
Nonspecific abnormalities 1 (10)
Normal 5 (50)
Histopathological analysis  
of muscle specimens  
under an electron  
microscope (n=10)
Pleoconia only 2 (20)
Megaconia only 1 (10)
Both pleoconia and megaconia 2 (20)
Normal 5 (50)
Genetic (n=16) Large-scale deletion of mtDNA 4 (25)
KSS, Kearns-Sayre syndrome; CPEO, chronic progressive external ophthal-
moplegia; MRI, magnetic resonance imaging; MRC, mitochondrial respira-
tory chain; mtDNA, mitochondrial DNA. 
Data are presented as numbers (percentages).
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Table 4. Comparisons of Clinical Variables among Patients with Different Types of Mitochondrial Diseases and Ophthalmoplegia
Clinical variables KSS and KSS-like (n=8) CPEO (n=8) p value
Patient characteristic
Sex (male) 5 (62.5) 4 (50) 0.500
First symptom
Ophthalmoplegia 2 (25) 4 (50) 0.304
Ptosis 4 (50) 2 (25) 0.304
Exercise intolerance 0 (0) 2 (25) 0.233
Afebrile seizure 1 (12.5) 0 (0) 0.500
Visual disturbance 1 (12.5) 0 (0) 0.500
Family history
Mitochondrial myopathy 0 (0) 1 (12) 0.500
Nonspecific neurological disease 1 (12.5) 2 (25) 0.500
None 7 (87.5) 5 (63) 0.285
Duration from birth to first symptom (month) 142.5 (106.5–189.5)  144.0 (29.8–255.0)  0.834
Duration from first symptom to last outpatient visit (month) 197.0 (146.0–220.0)  100.5 (58.0–139.5)  0.092
Duration from birth to muscle biopsy (month) 210.5 (198.3–279.0)  231.0 (46.8–451.5)  1.000
Duration from birth to cocktail therapy initiation (month) 240.0 (217.5–297.0)  203.5 (76.5–373.3)  0.668
Age at last outpatient visit (months) 321.0 (255.0–405.5) 220.0 (159.5–434.0) 0.834
Onset of ocular myopathy before 20 years of age 8 (100) 5 (63) 0.100
Clinical severity at last outpatient visit
Severe or death 1 (12.5) 0 (0) 0.500
Mild to moderate 1 (12.5) 0 (0) 0.500
Normal and asymptomatic 6 (75) 8 (100) 0.233
Clinical features
Eye
Progressive external ophthalmoplegia 8 (100) 8 (100) -
Ptosis 8 (100) 5 (67.5) 0.100
Pigmentary retinopathy 8 (100) 0 (0) <0.001
Ear (sensorineural hearing loss) 3 (37.5) 0 (0) 0.100
Respiratory system 1 (12.5) 2 (25) 0.500
Gastrointestinal tract 5 (62.5) 0 (0) 0.013
Heart
Abnormal conduction 5 (62.5) 0 (0) 0.013
Pacemaker treatment 3 (37.5) 0 (0) 0.100
Neuromuscular system
Seizure 2 (25) 2 (25) 0.715
Ataxia 1 (12.5) 0 (0) 0.500
Peripheral neuropathy 1 (12.5) 0 (0) 0.500
Extraocular muscle involvement 7 (87.5) 5 (67) 0.285
Endocrine system 2 (25) 2 (25) 0.715
Diagnostic evaluation
Lactic acidosis (n=14)
Severe 2/8 (25) 1/6 (17) 0.615
Mild 4/8 (50) 3/6 (50) 0.704
Normal 2/8 (25) 2/6 (33) 0.594
Creatine kinase (n=15)
Severe 3/8 (37.5) 0/7 (0) 0.154
Mild 2/8 (25) 2/7 (29) 0.594
Normal 3/8 (37.5) 5/7 (71) 0.296
Brain MRI (n=14)
Basal ganglia signal abnormality 1/7 (14.3) 2/7 (28.6) 0.500
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 In a study by García-Cazorla, et al.,18 most of the patients 
with mitochondrial disease died within the first 3 months (16 
of 33). Similarly, the prognosis of other mitochondrial diseas-
es is usually poor.19-21 However, the clinical severity of patients 
in our study was relatively mild. In cases of mitochondrial dis-
ease, the prognosis differs depending on the type of syndrome 
or pattern of organ involvement. The prognosis for mitochon-
drial diseases with ophthalmoplegia as a main symptom may 
be better than expected and reported. The reason for this 
would be that the main symptom is different and its onset age 
is later. Because of these varying prognoses, care and family 
counseling should be implemented according to the type of 
mitochondrial disease. The major prognostic factor in KSS is 
cardiac involvement, and indeed, complete heart block has 
been found to be a major cause of death in patients with 
KSS.22 Eight of the 16 patients in our study underwent cardiac 
treatment, and three received a pacemaker. Therefore, while 
the overall prognosis of KSS and CPEO may be good, the 
prognosis of patients with cardiac involvement could be dif-
ferent. Moreover, there are a few known protocols for deter-
mining the prognosis of the various phenotypes and geno-
types of this disease, and thus, a protocol for obtaining a dis-
ease-specific prognosis is desired.
With regard to the criteria for KSS, our study revealed signif-
icant differences in the prevalence of pigmentary retinopathy 
or cardiac involvement when compared with previous re-
ports.23 The results of our study indicated that the prevalence 
of gastrointestinal involvement was also significantly different 
between the CPEO and KSS/KSS-like groups. Gastrointestinal 
features of mitochondrial disease are expressed as recurrent 
vomiting, constipation, intestinal pseudoobstruction, and 
dysphagia.24 Because of these gastrointestinal problems, en-
teral tube feeding is also frequent in patients with mitochon-
drial diseases.25 In a paper by Finsterer,26 patients with KSS 
showed visceral manifestations, such as dysphagia and hepa-
topathy. KSS and PS may also cause exocrine pancreatic dys-
function and MELAS (mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like episodes) with intestinal pseu-
doobstruction. Gastrointestinal manifestations can be prima-
ry symptoms of KSS and CPEO, as demonstrated by our re-
sults. Therefore, gastrointestinal manifestations may appear 
as additional symptoms of systemic involvement, which can 
affect the prognosis. The clinical diagnosis would be improved 
if the phenotype could be more finely categorized.
Table 4. Comparisons of Clinical Variables among Patients with Different Types of Mitochondrial Diseases and Ophthalmoplegia
Clinical variables KSS and KSS-like (n=8) CPEO (n=8) p value
Thalamus signal abnormality 2/7 (28.6) 2/7 (28.6) 0.720
Brainstem signal abnormality 1/7 (14.3) 2/7 (28.6) 0.500
Midbrain 1/7 (14.3) 2/7 (28.6) 0.500
Pons 1/7 (14.3) 1/7 (14.3) 0.769
Medulla 1/7 (14.3) 2/7 (28.6) 0.500
Cortex signal abnormality 0/7 (0) 1/7 (14.3) 0.500
White matter signal abnormality 3/7 (42.9) 2/7 (28.6) 0.500
Diffuse atrophy 1/7 (14.3) 0/7 (0) 0.500
Cerebellar atrophy 0/7 (0) 2/7 (28.6) 0.231
Biochemical enzyme assay (n=10)
MRC complex I defect 3/6 (50) 2/4 (50) 0.548
MRC complex IV defect 1/6 (16.7) 0/4 (0) 0.738
Normal 2/6 (33.3) 2/4 (50) 0.600
Histopathological analysis under a light microscope (n=10)
Pathological findings in mitochondria 2/6 (33.3) 2/4 (50) 0.548
Nonspecific abnormalities 1/6 (16.7) 2/4 (50) 0.600
Normal 2/6 (33.3) 2/4 (50) 0.738
 Histopathological analysis under an electron microscope (n=10)
Pleoconia only 3/6 (50) 1/4 (25) 0.357
Megaconia only 2/6 (33.3) 1/4 (25) 0.595
Both pleoconia and megaconia 2/6 (33.3) 0/4 (0) 0.333
Normal 2/6 (33.3) 2/4 (50) 0.548
Genetic (n=16)
Large-scale deletion of mtDNA 4/8 (50) 0/8 (0) 0.038
KSS, Kearns-Sayre syndrome; CPEO, chronic progressive external ophthalmoplegia; MRI, magnetic resonance imaging; MRC, mitochondrial respiratory chain; mtD-
NA, mitochondrial DNA. 
Data are presented as a median (Interquartile range) or number (percentages). Fischer's exact tests and chi-square tests were used to evaluate differences be-
tween the groups. Mann-Whitney U tests were used to analyze the duration-related variables.
 (Continued)
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Mitochondrial diseases are rare, such that there are limited 
data about the diseases. Moreover, performing research is dif-
ficult. Because mitochondrial disease is heterogenous, it needs 
better classification and further studies to generalize its ho-
mogeneous aspects. In this study, the mean age and follow-
up duration were greater than those reported in other studies. 
In addition, our patients with KSS had gastrointestinal symp-
toms, which are not part of the existing definition for KSS and 
may indicate another aspect of systemic involvement. Since 
our subjects were included in the study based on their pheno-
types, not all patients had genotype abnormality. Although 
large-scale mtDNA deletions were not found in all patients 
with KSS, it was an objective diagnostic factor for the syn-
drome. Therefore, a gene study may prove helpful for evaluat-
ing patients with KSS. More research on the various types of 
mitochondrial diseases will increase the understanding of its 
natural course and improve clinical practice through early di-
agnosis, patient and family counseling, and selection of ap-
propriate treatments.
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